Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| SUMMER INFAN | SUMR | 6.93% |
| FEDERAL MOGU | FDML | 6.24% |
| NATUS MEDICA | BABY | 5.55% |
| NEW ORIENTAL | EDU | 5.44% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
JPMorgan Chase & Co. ( JPM - Analyst Report ) has ushered in some good news for its investors. In its latest quarterly filings, the company stated that it has received approval to restart share buybacks and the litigation related to Bear Stearns Cos. (acquired in 2008) is now settled and requires court approval.
JPMorgan stated that the Federal Reserve has granted approval to resume its share repurchase program in the first quarter of 2013, following the review of the company’s capital plan. Therefore, JPMorgan will be repurchasing $3 billion worth of shares during the above-mentioned period.
The need to resubmit the capital plan emerged owing to the huge trading loss in JPMorgan’s CIO division in May. Following this, the company temporarily suspended share repurchase program to rebuild its capital levels and meet the stringent regulatory capital.
Another overhang that got resolved is the settlement of a lawsuit that accused Bear Stearns of repackaging and selling residential loans to the investors. The investigation was being conducted by the Securities and Exchange Commission (SEC). Though the settlement deal is subject to the final approval of the District Court, the settlement amount is not disclosed.
The SEC was conducting an inquiry into the allegations against Bear Stearns that claimed that after receiving compensation from the loan originators for failed mortgages, the firm did not transfer the same to a trust that was managing residential mortgage-backed securities (RMBS). The SEC was also probing disclosures made to the investors regarding the renegotiated loans.
We believe the removal of these overhangs will prove to be modestly positive for both the investors and the company. Yet, JPMorgan continues to encounter many other probes and lawsuits from the investors and regulators pertaining to its role during the crisis. Along with these, the company is facing investigations for the trading debacle, its alleged role in rigging the LIBOR rates and for money laundering.
However, based on JPMorgan’s strong fundamentals, we anticipate continued synergies from a reduction in reserves for future losses, business diversification, steadily improving retail banking performance and strong capital position.
JPMorgan currently retains a Zacks #2 Rank, which translates into a short-term Buy rating. However, one of its peers, Bank of America Corporation ( BAC - Analyst Report ) , retains a Zacks #3 Rank (short-term Hold rating).
Read the full reports :
Analyst Report on JPM
Analyst Report on BAC